Cargando…

Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients

Zika virus has spread around the world with rapid pace in the last five years. Although symptoms are typically mild and unspecific, Zika’s major impact occurs during pregnancy, generating a congenital syndrome. Serology plays a key role in its diagnosis. However, its use is limited due to the uncert...

Descripción completa

Detalles Bibliográficos
Autores principales: Delfin-Riela, Triana, Rossotti, Martín A., Mattiuzzo, Giada, Echaides, César, González-Sapienza, Gualberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862682/
https://www.ncbi.nlm.nih.gov/pubmed/36668962
http://dx.doi.org/10.3390/tropicalmed8010055
_version_ 1784875149921615872
author Delfin-Riela, Triana
Rossotti, Martín A.
Mattiuzzo, Giada
Echaides, César
González-Sapienza, Gualberto
author_facet Delfin-Riela, Triana
Rossotti, Martín A.
Mattiuzzo, Giada
Echaides, César
González-Sapienza, Gualberto
author_sort Delfin-Riela, Triana
collection PubMed
description Zika virus has spread around the world with rapid pace in the last five years. Although symptoms are typically mild and unspecific, Zika’s major impact occurs during pregnancy, generating a congenital syndrome. Serology plays a key role in its diagnosis. However, its use is limited due to the uncertainty caused by the cross-reaction of antibodies elicited in response to other flavivirus infections when tested in direct immunoassays. Using a panel of previously generated anti-Zika non-structural protein 1 (NS1) nanobodies, a set was selected that only recognizes epitopes present in Zika and is immunogenic to humans. A proper arrangement of these nanobodies was made and conditions were optimized in order to develop a novel serology assay. This new ELISA relies on the inhibition of the binding of a set of selected nanobodies to Zika-immobilized NS1 when previously incubated with Zika convalescent sera. Using the developed blocking of binding assay, it was possible to discriminate between Zika-specific and cross-reactive antibodies in serum samples from infections with Zika and other flaviviruses.
format Online
Article
Text
id pubmed-9862682
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98626822023-01-22 Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients Delfin-Riela, Triana Rossotti, Martín A. Mattiuzzo, Giada Echaides, César González-Sapienza, Gualberto Trop Med Infect Dis Article Zika virus has spread around the world with rapid pace in the last five years. Although symptoms are typically mild and unspecific, Zika’s major impact occurs during pregnancy, generating a congenital syndrome. Serology plays a key role in its diagnosis. However, its use is limited due to the uncertainty caused by the cross-reaction of antibodies elicited in response to other flavivirus infections when tested in direct immunoassays. Using a panel of previously generated anti-Zika non-structural protein 1 (NS1) nanobodies, a set was selected that only recognizes epitopes present in Zika and is immunogenic to humans. A proper arrangement of these nanobodies was made and conditions were optimized in order to develop a novel serology assay. This new ELISA relies on the inhibition of the binding of a set of selected nanobodies to Zika-immobilized NS1 when previously incubated with Zika convalescent sera. Using the developed blocking of binding assay, it was possible to discriminate between Zika-specific and cross-reactive antibodies in serum samples from infections with Zika and other flaviviruses. MDPI 2023-01-10 /pmc/articles/PMC9862682/ /pubmed/36668962 http://dx.doi.org/10.3390/tropicalmed8010055 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Delfin-Riela, Triana
Rossotti, Martín A.
Mattiuzzo, Giada
Echaides, César
González-Sapienza, Gualberto
Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title_full Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title_fullStr Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title_full_unstemmed Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title_short Nanobody-Based Blocking of Binding ELISA for the Detection of Anti-NS1 Zika-Virus-Specific Antibodies in Convalescent Patients
title_sort nanobody-based blocking of binding elisa for the detection of anti-ns1 zika-virus-specific antibodies in convalescent patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862682/
https://www.ncbi.nlm.nih.gov/pubmed/36668962
http://dx.doi.org/10.3390/tropicalmed8010055
work_keys_str_mv AT delfinrielatriana nanobodybasedblockingofbindingelisaforthedetectionofantins1zikavirusspecificantibodiesinconvalescentpatients
AT rossottimartina nanobodybasedblockingofbindingelisaforthedetectionofantins1zikavirusspecificantibodiesinconvalescentpatients
AT mattiuzzogiada nanobodybasedblockingofbindingelisaforthedetectionofantins1zikavirusspecificantibodiesinconvalescentpatients
AT echaidescesar nanobodybasedblockingofbindingelisaforthedetectionofantins1zikavirusspecificantibodiesinconvalescentpatients
AT gonzalezsapienzagualberto nanobodybasedblockingofbindingelisaforthedetectionofantins1zikavirusspecificantibodiesinconvalescentpatients